A Chemotherapy-Free Regimen of Tucatinib and Trastuzumab Shows Antitumour Activity with Durable Responses in Patients with HER2-mutated MBC By Ogkologos - January 29, 2025 596 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SGNTUC-019 study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR How I Found a Meaningful Career After Cancer October 26, 2020 Happy Nurses Month! May 3, 2021 Engaging People with Low-Grade Glioma in Cancer Research August 24, 2023 Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in... July 16, 2025 Load more HOT NEWS EMA Recommends Granting a Conditional Marketing Authorisation for Zanidatamab How Does COVID-19 Affect People with Cancer? NCCAPS Will Help Find... Why I Work to Bridge the Gap Between People With Cancer... Shorter, More Intensive Radiation Safe after Surgery for Prostate Cancer
